臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 總筆數 :0
	造訪人次 : 52899872 線上人數 : 1015 教育部委託研究計畫計畫執行:國立臺灣大學圖書館

搜尋範圍

進階搜尋

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"hsu c h"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 516-525 / 1656 (共166頁)
<< < 47 48 49 50 51 52 53 54 55 56 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2021-03-09T06:46:15Z	Prognostic value of multidrug resistance 1, glutathione-S-transferase-�k and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy	Hsu C.-H.;Chen C.-L.;Ruey-Long Hong;Chen K.-L.;Lin J.-F.;Cheng A.-L.; Hsu C.-H.; Chen C.-L.; RUEY-LONG HONG; Chen K.-L.; Lin J.-F.; Cheng A.-L.
臺大學術典藏	2021-03-09T06:46:06Z	Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy	Lin Z.-Z.; Hsu C.; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; RUEY-LONG HONG; Hsu C.-H.; Chengb A.-L.
臺大學術典藏	2021-03-09T05:18:40Z	Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract	Hsu C.; Ying-Chun Shen; Yang C.-H.; Yeh K.-H.; Lu Y.-S.; Hsu C.-H.; Liu H.-T.; Li C.-C.; Chen J.-S.; Wu C.-Y.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:37Z	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma	Hsu C.-H.; Ying-Chun Shen; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:36Z	Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma	Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:35Z	Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil	Hsu C.-Y.; Ying-Chun Shen; Yu C.-W.; Hsu C.; Hu F.-C.; Hsu C.-H.; Chen B.-B.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F.
臺大學術典藏	2021-03-09T05:18:34Z	High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy	Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:33Z	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems	Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:31Z	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma	Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:31Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Ying-Chun Shen; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.

顯示項目 516-525 / 1656 (共166頁)
<< < 47 48 49 50 51 52 53 54 55 56 > >>
每頁顯示[10|25|50]項目